A Phase 1, MultiCenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 Administered Orally Twice Weekly for Three Weeks of a Four Week Course or Twice Weekly for Four Weeks of a Four Week Course to Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs CNF 2024 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Biogen Idec
- 20 May 2009 Additional lead trial investigator identified as Chris Storgard as reported by ClinicalTrials.gov.
- 20 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.